Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation.

Jordan SC, Reinsmoen N, Lai CH, Cao K, Kahwaji J, Peng A, Villicana R, Vo A.

Transplant Proc. 2012 Jan;44(1):60-1. doi: 10.1016/j.transproceed.2011.12.028.

PMID:
22310579
2.

Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.

Jin MK, Cho JH, Kwon O, Hong KD, Choi JY, Yoon SH, Park SH, Kim YL, Kim CD.

Transplant Proc. 2012 Jan;44(1):200-3. doi: 10.1016/j.transproceed.2011.11.040.

PMID:
22310614
3.
4.

Highly Sensitized Patients: Miami Transplant Institute Experience.

Mattiazzi AD, Centeno A, Amador A, Fernandez-Bango C, Scowby CD, O'Rourke M, Hill-Matthie T, Patel R, Barrios F, Ruiz P, Chen L, Saghesima J, Ciancio G, Burke GW, Goldstein M, Chandar J, Contreras G, Roth D, Kupin W, Guerra G, Vianna R.

Clin Transpl. 2014:171-8.

PMID:
26281142
5.

Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.

Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, Reinsmoen NL, Villicana R, Jordan SC.

Transplantation. 2010 May 15;89(9):1095-102. doi: 10.1097/TP.0b013e3181d21e7f.

PMID:
20110854
6.

Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.

Vo AA, Choi J, Cisneros K, Reinsmoen N, Haas M, Ge S, Toyoda M, Kahwaji J, Peng A, Villicana R, Jordan SC.

Transplantation. 2014 Aug 15;98(3):312-9. doi: 10.1097/TP.0000000000000064.

PMID:
24770617
7.

Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy.

Lai CH, Cao K, Ong G, Naim M, Wang Q, Mirocha J, Vo A, Jordan SC, Reinsmoen NL.

Transplantation. 2011 Jul 15;92(1):48-53. doi: 10.1097/TP.0b013e31821eab8a.

PMID:
21562450
8.

Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.

Tanimine N, Ide K, Yamashita M, Tanaka Y, Igarashi Y, Banshodani M, Tazawa H, Basnet NB, Doskali M, Onoe T, Tashiro H, Ohdan H.

Transplant Proc. 2011 Jul-Aug;43(6):2411-4. doi: 10.1016/j.transproceed.2011.05.039.

PMID:
21839279
9.

Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.

Vo AA, Sinha A, Haas M, Choi J, Mirocha J, Kahwaji J, Peng A, Villicana R, Jordan SC.

Transplantation. 2015 Jul;99(7):1423-30. doi: 10.1097/TP.0000000000000525.

PMID:
25606792
10.

Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients.

Montgomery RA, Lonze BE, Jackson AM.

Curr Opin Organ Transplant. 2011 Aug;16(4):439-43. doi: 10.1097/MOT.0b013e32834897c1. Review.

PMID:
21666478
11.

Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.

Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, Wang Q, Jordan SC.

Transplantation. 2008 Sep 27;86(6):820-5. doi: 10.1097/TP.0b013e3181856f98.

PMID:
18813107
12.

Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab.

Lobashevsky AL, Higgins NG, Rosner KM, Mujtaba MA, Goggins WC, Taber TE.

Transplantation. 2013 Jul 27;96(2):182-90. doi: 10.1097/TP.0b013e3182962c84.

PMID:
23778648
13.
14.
15.

Transplantation of the broadly sensitized patient: what are the options?

Böhmig GA, Wahrmann M, Bartel G.

Curr Opin Organ Transplant. 2011 Dec;16(6):588-93. doi: 10.1097/MOT.0b013e32834c23ba. Review.

PMID:
21971512
16.

Kidney paired donation in the presence of donor-specific antibodies.

Blumberg JM, Gritsch HA, Reed EF, Cecka JM, Lipshutz GS, Danovitch GM, McGuire S, Gjertson DW, Veale JL.

Kidney Int. 2013 Nov;84(5):1009-16. doi: 10.1038/ki.2013.206. Epub 2013 May 29.

17.
18.

Low median fluorescence intensity could be a nonsafety concept of immunologic risk evaluation in patients with shared molecular eplets in kidney transplantation.

Bosch A, Llorente S, Diaz JA, Salgado G, López M, Boix F, López-Hernández R, González-Soriano MJ, Campillo JA, Moya-Quiles MR, Perez-Lopez N, Minguela A, Jimeno L, Alvarez-López MR, Muro M.

Hum Immunol. 2012 May;73(5):522-5. doi: 10.1016/j.humimm.2012.02.020. Epub 2012 Mar 6.

PMID:
22425738
20.

Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab.

Vo AA, Petrozzino J, Yeung K, Sinha A, Kahwaji J, Peng A, Villicana R, Mackowiak J, Jordan SC.

Transplantation. 2013 Mar 27;95(6):852-8. doi: 10.1097/TP.0b013e3182802f88.

PMID:
23511212

Supplemental Content

Support Center